The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

Dina Baier, Beatrix Schönhacker-Alte, Mate Rusz, Christine Pirker, Thomas Mohr, Theresa Mendrina, Dominik Kirchhofer, Samuel M. Meier-Menches, Katharina Hohenwallner, Martin Schaier, Evelyn Rampler, Gunda Koellensperger, Petra Heffeter, Bernhard Keppler, Walter Berger (Corresponding author)

Publications: Contribution to journal › Article › Peer Reviewed

Fingerprint

Dive into the research topics of 'The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry